On October 21, 2026 Okomera, a TechBio company pioneering personalized cancer care through a proprietary technology platform combining tumor mini-avatars, microfluidics, and AI-powered imaging, reported the signing of a commercial agreement with Servier, an independent international pharmaceutical group, to use its technology in the development of new cancer treatments.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
With more than 90% of oncology drug candidates never reaching the market, identifying early on the therapeutic approaches most likely to succeed is a critical challenge for the pharmaceutical industry. Okomera’s technology helps precisely reduce this attrition, by steering development toward candidates that demonstrated real, measurable activity against tumors.
This collaboration marks an important milestone for Okomera, which is signing its first commercial agreement with an international pharmaceutical group. Under the terms of the agreement, Servier will operate Okomera’s platform fully independently. Its teams will be able to generate standardized spheroid cultures, assess the response of these "miniaturized tumor avatars" to potential treatments, and generate actionable data on key biological mechanisms to support the development of new therapies, notably for pancreatic cancer and glioblastoma.
Nicolas Molinié, Group Leader Target Discovery at Servier, said: "Okomera’s technology allows us to easily generate standardized data from human tumor models. The integrated platform will help us better characterize treatment response mechanisms and identify faster the most promising therapeutic avenues."
Silvère Lucquin, CEO of Okomera, added: "We are particularly proud of this collaboration with Servier, which underscores the value of our platform in meeting the needs of both industry and research teams developing new therapies. This agreement is the result of several years of R&D efforts and reflects the growing adoption of our technology."
Okomera deploys its technology across the entire therapeutic innovation value chain: from preclinical research, as with Servier, to clinical trials and patient care by clinicians. Using patient biopsies, its miniaturization technology reproduces tumor behavior and analyzes how tumors respond to different treatments. Designed as a decentralized laboratory, it delivers the capabilities of a state-of-the-art infrastructure within a single machine, enabling users to independently manage the entire workflow, from culture generation to actionable data production.
Today, nearly one in two oncology patients does not respond to their initial treatment. By placing patient biology at the heart of therapeutic decision-making, Okomera is paving the way for a new generation of precision medicine.
(Press release, Servier, OCT 21, 2026, View Source [SID1234673657])